Prospective, Multicenter, Single-Arm, Phase Ⅱ Clinical Study on the Efficacy and Safety of Sacituzumab Tirumotecan Combined With Bevacizumab in Platinum-Resistant Recurrent Ovarian Cancer
Clinical trial NCT07314619 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07314619
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-12-30
- Primary completion
- 2027-12-30
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.